腮腺导管癌的临床病理特征分析--附1例报告及文献复习

目的:结合文献探讨腮腺导管癌的临床病理特征。方法:报道1例腮腺导管癌，就本病的临床生物学特征、病理、治疗及预后进行总结分析。结果:经手术及放疗后3个月复查，出现同侧颈部淋巴结转移。结论:腮腺导管癌是一类恶性度很高的恶性肿瘤，诊断主要依靠术后病理学及免疫组织化学检查，以局部广泛切除加颈廓清术为主，术后给予放疗。     

人脐血中血管内皮祖细胞体外扩增和鉴定的实验研究

目的：探讨从人脐血中分离、培养、体外扩增血管内皮祖细胞(EPC)的方法及体外进行EPC的鉴定。方法：采用密度梯度离心法从脐血中分离EPC，体外分别培养在包被有FN和不包被FN的培养皿中，采用免疫组织化学技术(SABC法)鉴定培养贴壁细胞表面标志CD31、CD34及KDR的表达；流式细胞仪检测细胞表面标志CD133及表达CD133细胞比例。结果：包被FN的培养皿中细胞贴壁及增殖均比未包被的多，免疫组化染色CD31、CD34及KDR均呈阳性，培养第4天流式细胞仪检测CD133^ 占21．3％。结论：密度梯度离心法可用于体外分离脐血中EPC进行实验研究，FN对于体外培养EPC有非常重要的作用。     

Role of 4-1BB in Allograft Rejection Mediated by CD8+ T Cells

Blockade of traditional costimulatory molecules fails to inhibit rejection in many models where CD8+ T cells are sufficient to mediate rejection. This observation demonstrates that in many settings CD8+ T cells are not dependent upon CD28 or CD154 signals to mediate rejection. 4-1BB (CD137) has been shown to be an important regulatory molecule for CD8+ T cells in a variety of nontransplant models. Here we show that blocking the 4-1BB pathway significantly inhibited rejection of intestinal allografts by CD8+ but not CD4+ T cells. This effect was associated with significantly decreased expression of the genes encoding TNFalpha and secondary lymphoid chemokine (SLC) within the spleens of recipient mice. Disruption of the 4-1BB pathway also impaired the priming of alloantigen-specific CD8+ T cells and the accumulation of recipient dendritic cells within the spleen. These data directly demonstrate an important role for 4-1BB in allograft rejection; particularly rejection mediated by CD8+ T cells. Our data suggest that in addition to providing a direct costimulatory signal to T cells, the 4-1BB pathway may regulate other important steps in the immune response such as the migration of T cells and dendritic cells.     

广东省结核病流行菌株研究

目的：从分子流行病学的角度探讨广东省结核分支杆菌菌株流行的分布。方法：构建广东省74株临床分离的以RFLP为基础的结核分支杆菌的IS6110 DNA指纹图谱技术，确诊结核分支杆菌菌株的流行分布。结果：24．3％（18／74）的结核菌株的IS6110 DNA指纹相似值在1－0．65之间，鉴定结果为它们均是“北京家族”结核分支杆菌菌株。结论：广东省结核菌株流行主要存在着遗传关系接近，在基因水平上相关程度较高的“北京家族”结核分支杆菌菌株，且该家族菌株正以一定的比例在我省流行。     

改良静脉输液排气法

为缩短静脉输液排气时间，提高一次排气成功率，对传统排气方法进行了改进，效果良好。现介绍如下。     

隐性脊柱裂排尿功能异常的临床特征

目的：研究伴有排尿功能障碍的隐性脊柱裂患者临床特征。方法：总结41例有明显排尿功能障碍的隐性脊柱裂患者临床资料。以18岁为界，将患者分为儿童组和成人组，所有患者均接受X线检查，除4例儿童外，均接受普通尿流动力学检查。结果：儿童组发病高峰年龄在1～2岁，主要临床表现为持续性原发性遗尿，部分伴有尿频、尿急及轻度急迫性尿失禁现象；成人组发病高峰年龄在18～26岁，主要临床表现为尿频、尿急、排尿前踌躇、排尿困难、遗尿等。结论：隐性脊柱裂患者常有排尿功能异常表现，出现症状的高峰时间为出生后及青春发育期后。X线、CT、MRI和尿流动力学等检查在隐性脊柱裂排尿功能障碍的诊断和治疗方案制定中有重要地位。     

A Synergistic Effect Between PG490-88 and Tacrolimus Prolongs Renal Allograft Survival in Monkeys

This study was undertaken to determine if PG490-88 and tacrolimus (Tac) act synergistically to prevent renal allograft rejection in monkeys and to explore possible mechanisms of synergy between these agents. MHC-mismatched renal allografts were transplanted into cynomolgus monkeys after bilateral nephrectomy. Recipients were divided into the following groups: (i) no treatment; (ii) PG490-88 (0.03 mg/kg); (iii) Tac (1 mg/kg); (iv) PG490-88 (0.01 mg/kg) + Tac (1 mg/kg) and (v) PG490-88 (0.03 mg/kg) + Tac (1 mg/kg). Through synergy PG490-88 and Tac inhibited anti-CD3/PMA-induced T-cell proliferation and IFN-gamma expression in vitro. Tac monotherapy only marginally prolonged survival (27 +/- 3.2 days), while the combination of PG490-88 and Tac significantly prolonged graft survival to a median of 99 days (PG490-88 at 0.03 mg) and 38.5 days (PG490-88 at 0.01 mg/kg). Prolonged survival correlated with inhibited IgM production as well as reduced T-cell infiltration, IL-2 protein expression and NF-AT/NF-kappaB activity. We conclude that PG490-88 and a subtherapeutic dose of Tac significantly prolong renal allograft survival in monkeys through the synergistic inhibition of T-cell activation and a decrease in IFN-gamma production and NF-AT/NF-kappaB activity.     

肝癌经导管动脉灌注化疗栓塞术疗效的MR扩散加权成像动态研究

目的探讨MR扩散加权成像(DWI)在原发性肝癌经导管动脉化疗栓塞术(TACE)疗效动态评价中的作用。方法在1.5TGE Signa Twin speed MR机上,取扩散敏感梯度因子(b值)为0及800s/mm2,利用固定参数组合的自旋回波-平面回波(SE-EPI)序列对首次行TACE治疗的25例肝癌肿块分别于术前24~48h、术后36~48h、术后7~10d、术后30~38d内各进行1次DWI,对每次的图像进行后处理,计算出每例肝癌每个时点的表观扩散系数(ADC值),对各个时点的ADC值进行对比研究,并结合第1次TACE术后与第2次TACE术前肿瘤的血管造影染色及碘油沉积的改变判断肿瘤的复发情况。结果术前24~48h、术后36~48h、术后7~10d、术后30~38d组的ADC值分别为(1.376±0.012)×10-3mm2/s、(1.598±0.012)×10-3mm2/s、(1.723±0.012)×10-3mm2/s、(1.684±0.012)×10-3mm2/s。术后各组肝癌组织的ADC值较术前明显升高(P<0.05);术后7~10d、术后30~38d组的ADC值较术后36~48h组明显升高(P<0.05);术后30~38d的ADC值较术后7~10d组明显降低(P<0.05)。将第1次TACE术后与第2次TACE术前的造影片及碘油沉积片对比见术后30~38d ADC值下降的肝癌病例都有不同程度的复发,ADC值下降明显的复发也最为明显。结论利用MR DWI技术对肝癌组织的ADC值进行动态观察,可以评价肝癌TACE术后癌组织的坏死、复发情况。     

用结合^131碘和化疗药物的明胶微球作肝动脉...

Nine patients with inoperable hepatoma were treated by using hepatic arterial embolization 131I and chemotherapeutic agent gelatin microsphere (131I-CA-GM). The emission CT after operation detected that the microspheres were concentrated on tumor area. The ratio between the radioactivity in tumor and that in liver was 4.1:1. A case died of ictopic embolization; the others survived 3, 4, 5, 19, 24, 7, 8, and 12 months respectively. Three of them were still alive. 131I-CA-GM has triple anticarcinogenic actions, including the arterial occlusion, targeting chemotherapy and internal radiation. The microspheres can selectively accumulate in the tumor artery and can be easily traced by gamma-camera or emission CT. 131I-CA-GM is a hopeful embolic agent for the treatment of liver cancer, but some problems about ectopic arterial embolization should be further studied.